Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

BioGaia, Audiocast, Q2'26

By Inderes7/17/2026, 7:30 AM
BioGaia

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Theresa Agnew
00:00 - 07:55

This is Theresa Agnew, CEO of BioGaia, and I am here with Alexander Kotsinas, and we are here to present our Q2 2026 results. Some of the highlights of the quarter are that growth, excluding currency effects, was 12% versus a year ago. Our EBIT margin is 30%, with an adjusted EBIT margin of 33% for the quarter. Overall, our net sales reached 441 million SEK. As I said, with growth excluding currency effects of 12%, specifically in the regions in EMEA, our sales increased by 21%, excluding currency effects. In the Americas, sales increased by 16% excluding currency effects, while Asia-Pacific decreased by 6% excluding currency effects due to order variability. Our operating profit in the quarter was 132 MSEK, which is an increase of 22%, and our EBIT margin was 30% versus the 27% last year for Q2; our adjusted EBIT margin was 33% for the quarter. Overall, our net sales year-to-date reached 813 MSEK, representing growth of 13% excluding currency effects. Our BioGaia company strategy remains the same. Our first strategic pillar is to grow the core, the core being our health areas of business, of which gut health, including colic, oral health, and immune health, are our biggest priorities. Our second strategic pillar is what we call expansion through direct markets, where we look at particular markets to transition from a distributor partnership to a subsidiary or direct market. We currently have 12 direct markets, and our third strategic pillar is breakthrough innovation. This is a market creation opportunity for probiotics, where people do not routinely use probiotics today. The foundations of our company are people and culture, investing for profitable growth, using digital as an enabler, both in how we go to market through our omnichannel approach, as well as digitizing our business internally, driven by science, which has been a foundation for over 30 years, and sustainable solutions, highlighting the importance of sustainability to our business. So, how are we delivering on our strategy in terms of growing the core? In the quarter, we drove growth for both the Pediatric and Adult Health segments. We are investing in our marketing and selling activities to drive strong growth in our direct markets. We are continuing to roll out our new products. We had originally launched BioGaia Gastrus Pure Action in October of 2024. We continue to roll that out this year. We also launched last year BioGaia Prodentis Fresh Breath. We are continuing to roll that out to more markets this year. And we just recently in May launched our next generation patented probiotic drops called BioGaia Protectis Plus. BioGaia Protectis Plus. BioGaia Protectis Plus will be available in addition to our original Protectis drops. And in terms of expansion through direct markets, we continued our rollout in Germany and Austria in Q2, which originally launched in January of this year. One of our largest markets, the US, had record sales in Q2, and we have seen strong performance in France in Q2 in terms of our breakthrough innovation. Skin health is one of our exciting new areas, and we expanded our portfolio in the quarter with two additional new products and updated our design across the full range. So some of the launches that we had in the quarter, as I mentioned, we launched BioGaia Protectis Plus; we launched that in the UK, Ireland, as well as in Sweden. We launched our Pharax drops in a number of markets. As I mentioned, we launched our two new skincare products. So, a face and body lotion and a balm-to-milk body wash, both microbiome-friendly and containing organic ingredients. And those launches happened in the US and China. Some of the key events for the quarter. On April 28th, we published some new scientific findings on one of our patented technologies. It is called LongevityGuard. It is a desiccant technology that goes into our drops products and our probiotic ointment that improves the stability and shelf life of our probiotics so that they remain viable throughout the shelf life. On May 7th, we announced the launch of BioGaia Protectis Plus, which is, as I mentioned, a proprietary patented combination of our strain DSM 17938, as well as BG-R46. Also on May 7th, at our Annual General Meeting, we elected a new board member to our Board of Directors. Amy Byrick. And then on June 18th, we announced the new product launches that I mentioned, the lotion and wash for the BioGaia skincare portfolio. Our growth, as I said, for Q2, was 12% organic growth. As you look at it from a pediatric and adult segment standpoint, the pediatric segment grew 9% organically, and the adult segment grew 23% organically. And a little bit more on the segments if you look at the quarter. As I said, excluding currency effects, Pediatrics grew 9% and Adult Health grew 23%. But if you look at the total for the year-to-date, the Pediatric segment grew 11% organic growth and Adult Health grew 21%. In terms of pediatrics for the quarter, sales mainly increased in France, the US, and Brazil. In terms of adult health, sales increased in our BioGaia Protectis tablets, and sales also increased in Asia Pacific, mainly in Indonesia and Japan. So overall, our pediatric segment for the quarter accounts for 75% of our sales. And year to date is 74% of our sales. Now by region, as I said previously, Europe, Middle East, and Africa increased by 21%, excluding currency effects, mainly in France and Poland. These were strong markets for us. In addition, other strong markets in EMEA were Germany as well as the UK. In Asia Pacific, our sales decreased by 6% excluding currency effects. Sales were lower in our pediatric segment, while the adult health segment did increase. As I mentioned previously, the sales were lower, mainly in China and South Korea. This was due to quarterly variations for individual orders. So, order variability. And in the Americas, which includes Latin America as well as North America, our sales increased by 16%, excluding currency effects. This is due to higher sales in both the Pediatric segment and the Adult Health segment, and sales increased mainly in the US, Canada, and Argentina. I will now turn it over to Alexander Kotsinas to go through the financials in more detail.

Alexander Kotsinas
07:55 - 12:07

Thank you Theresa. So to summarize, as we heard Theresa mention, we had a sales growth of 9% from 405 MSEK to 441 MSEK in the quarter. Gross profit also increased by 9%, and our operating profit increased by 22%. And we had an EBIT margin of 30% in the quarter compared to 27% one year ago. If we look at the sales, as we heard, we had a growth of 9% and we had a negative currency effect of 3%, and thus growth excluding currency effects of 12% in the quarter. Our gross margin in the quarter was 73%, which was at the same level as last year. We had one percentage point higher margin in the Pediatric segment and 1% lower in the Adult Health segment. That variation is mainly due to mix effects, some movements between different products and geographic markets. That explains the variation. And then if we look year-to-date, we have a margin of 72% versus 73% one year ago, with a slightly lower margin in the Adult Health segment. If we look at our operating expenses, our total operating expenses were 189 MSEK versus 186 MSEK. So 2% higher versus one year ago. Our sales and marketing expenses increased due to higher expenses for sales and marketing activities, mainly in our subsidiaries, for example, in France and Germany, which are new markets where we were spending less. One year ago. The sales and marketing expenses also include a one-time expense of 11.3 million SEK. Our R&D costs decreased, mainly due to lower costs for clinical studies. It is a normal variation between the quarters, and we have a positive effect in the other OPEX due to some exchange gains on receivables of 7 million SEK. And therefore, we have an OPEX of 189 million SEK versus 186 million SEK, which is 2% higher. And on an adjusted basis, our OPEX was 177 million versus 186, which is 5% lower compared to one year ago. And then if we summarize and look at our profit and loss statement again, we see an increase in sales of 9%, and an increase of OPEX at a lower extent of 2%. And therefore our EBIT increased by 22%. And on an adjusted basis, our EBIT increases by 32%. And we then have a margin of 30% in the quarter. On an adjusted basis, our margin is 33% and earnings per share were 1.02 SEK versus 0.87 SEK, an increase of 17% in the quarter. If we look at our cash flow, cash flow from operating activities amounted to 51 MSEK, and the decrease in cash flow from operating activities compared to the same period last year is mainly due to a negative change in working capital. It is also, I would say, a normal variation between the quarters, whereby we have some higher receivables, a bit higher inventory, and lower payables, with all three giving a negative effect. Then the change in working capital and the cash flow from financing activities amounted to -466 million. That then includes the additional purchase payment that we did for Nutraceutics, our US company, of 59.5 million SEK, which we paid on the 1st of April in this quarter. We also had dividends in the quarter of 405 MSEK. And the net effect is a cash flow for the period of -428 MSEK versus -624 MSEK in the same quarter last year. And we have cash at the end of the period of 446 million SEK. So with that, I hand over to Theresa Agnew for some concluding remarks.

Theresa Agnew
12:08 - 14:40

In summary, our second quarter showed growth, excluding currency effects, of 12%. Both our segments grew for the quarter. The pediatric segment grew 9%, excluding currency effects, and the adult segment grew 23%, excluding currency effects. And the increases were primarily driven by our BioGaia Protectis drops, our BioGaia Prodentis, and our BioGaia Gastrus Pure Action products. Europe. Middle East and Africa is regaining momentum, as you saw in key markets following a period of transition as we moved from partner distribution to direct market operations in France, Germany, and Austria. So our sales overall increased by 21%, excluding currency effects. France, as I said, was established as a direct market in April of 2025. Germany in January of 2026. Both contributed to the strong performance in EMEA. For Asia Pacific, our sales decreased by 6%, excluding currency effects. This was mainly due to lower sales in the pediatric segment. The Adult Health segment increased, as I mentioned previously, but sales decreased mainly in China and South Korea with our partners in those markets, and that was due to quarterly variations in individual orders. The Americas delivered strong performance with a 16% growth. Excluding currency effects. Both Canada and the US had robust growth in sales of our adult products, specifically BioGaia Prodentis and BioGaia Gastrus Pure Action, as well as double-digit growth in sales of our BioGaia Protectis drops. Our operating margin for the quarter was 30%. Our adjusted operating margin was 33%. So overall, our year-to-date adjusted operating margin is 30% compared to 27% last year. We are announcing that we will host a Capital Markets Day in London in December of this year, with more information to come on that. And we remain, of course, focused on driving our growth by leveraging our strong scientific foundation that we have built over many years. We are expanding our presence in key markets by continuing to launch new products in these markets and, of course, investing in increasing our brand visibility and our brand recommendations through healthcare professionals. So we will open it up now for any questions that you may have.

Operator
14:42 - 15:01

If you wish to ask a question, please dial star five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Christopher Lilienberg from Carnegie. Please go ahead.

Christopher Lilienberg
15:03 - 15:46

Thank you. Good morning. I have a few questions. But they are short, I promise. So first, the higher investments compared with the second quarter last year, if you could just comment on that. And I wonder about the gross margin improvement second quarter versus first quarter, if that is just a mix effect or if it is something else. The third question is if you could provide the figure for the direct sales market proportion of total sales for the quarter or year-to-date. And finally, if you are willing to comment on when you expect the China distributor to start ordering again. Thank you.

Theresa Agnew
15:48 - 15:50

What was the fourth question again?

Christopher Lilienberg
15:52 - 15:59

When do you expect the distributor in China to start ordering again? China. Yeah.

Theresa Agnew
16:00 - 16:05

Okay. So, the first two questions I will have Alex address.

Alexander Kotsinas
16:05 - 16:29

So, the investments in the quarter. Yeah. That is mainly BioGaia production. We are ramping up our investment levels. We are expanding our manufacturing capacity. So we will see a higher CapEx level for this year and also next year. And that is why you have a higher CapEx. We have actually had an abnormally low CapEx for the last year or two. Because we have been preparing for this.

Christopher Lilienberg
16:29 - 16:37

Yeah. Is this the level we saw in the quarter? Do you think that is a good representation for the remainder of the year?

Alexander Kotsinas
16:39 - 16:55

It will vary a bit going up and down, but it is difficult to say. It depends on the speed of the deployment of those investments. But I think for this year, we could have investments around 30 to 40 million SEK in total.

Christopher Lilienberg
16:57 - 16:58

Okay. That is helpful. Thank you.

Alexander Kotsinas
16:58 - 17:12

Yeah. And then for the gross margin, yes. As you guessed, it is mainly due to normal variations between geography and products. It is not the case that we have changed any pricing or anything similar.

Theresa Agnew
17:14 - 17:33

And then in terms of the direct market percentages. So for the quarter, our direct markets are 41% of our sales. And year-to-date, it is 45%. And then in terms.

Christopher Lilienberg
17:33 - 17:37

Of the sales, do you mean of the sales or of the action?

Unknown 1
17:37 - 17:38

Oh, I'm sorry. Of the sales.

Theresa Agnew
17:38 - 17:50

Apologies. Of our sales. So, 41% for the quarter represents direct markets, and 45% of our year-to-date sales are from direct markets.

Christopher Lilienberg
17:50 - 18:12

But I guess that leads us into my final question. So if APAC is picking up again, I guess that number should go down. Or is the trend so strong that the direct sales proportion will still continue to rise this year, would you say?

Unknown 1
18:13 - 18:13

No, that number.

Theresa Agnew
18:13 - 18:30

It will go down because we had lower orders for China and South Korea in the first half of the year. So we do expect, and that gets to your fourth question, that our China distributor will increase their orders in Q3 and then larger orders in Q4 as well.

Christopher Lilienberg
18:34 - 18:40

Okay. So do you expect China third quarter sales to be up year over year?

Theresa Agnew
18:41 - 18:42

Yes, we do.

Christopher Lilienberg
18:44 - 18:45

Okay. Thank you.

Operator
18:52 - 18:57

The next question comes from Philip Wetterqvist from SB1 Markets. Please go ahead.

Philip Wetterqvist
18:59 - 19:14

Hi. Good morning guys. I just have a couple of questions. My first question is on the extraordinary sales costs. Can you elaborate a little bit more on what that relates to? And did it impact cash flow here in the quarter?

Unknown 1
19:18 - 19:20

Well, in terms of the overall.

Theresa Agnew
19:21 - 19:31

In terms of the overall expense, it is a one-time expense. This is confidential for competitive reasons. So we do not share the specifics on that. But it is a one-time selling expense.

Alexander Kotsinas
19:32 - 19:35

And it did impact the cash flow in the quarter. That is correct.

Philip Wetterqvist
19:38 - 20:09

Okay. Thank you. And then my second question is still on the selling costs, and excluding the extraordinary expense, selling expenses grew 3% year-over-year, below the 12% organic growth. Should we assume selling expenses to grow slower than sales from Q2 onwards? Or is this a good run rate for H2, or how should we think about selling expenses going forward?

Alexander Kotsinas
20:11 - 20:50

It is a bit tricky to give an exact answer on that. On one hand, yes, we are trying to contain our costs. I mean, last year we had this global marketing campaign, for example, which we are not doing this year. So we will have a lower sales and marketing cost for that. On the other hand, we are ramping up our costs in the sales and marketing area in terms of, for example, direct operations in Germany that we did not have last year. And also we are ramping up in France and some other direct markets. So we do not provide exact guidance on the proportion of marketing and sales spending. But as we mentioned before, we're committed to keeping our total OPEX basically flat for this year.

Philip Wetterqvist
20:52 - 20:54

Okay. That was all for me. Thank you.

Alexander Kotsinas
20:54 - 20:55

Thank you.

Operator
20:59 - 21:10

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. The next question comes from Matthias Radstone from SEB. Please go ahead.

Matthias Radstone
21:13 - 21:30

Hi. Thanks for taking my questions. I have two. So in EMEA now, when you look at the performance, would you say it is anything in that region that is not performing according to plan, or is it really a good performance across the key markets?

Unknown 2
21:31 - 21:33

Uh, yeah. So in terms of.

Theresa Agnew
21:33 - 22:19

Europe, Middle East, and Africa have a couple of countries I would say are not performing to plan. So Turkey is one where we have switched our distributor partner earlier this year. So that business is going to start ramping up in the second half. That business has been poor in the first half of this year and also the second half of last year. So Turkey, and I would also say Italy, is slower than expected in terms of orders from our partner. That has to do with some of the probiotics market in Italy overall declining. But we have a high share and we are growing our share in that market.

Matthias Radstone
22:21 - 22:39

Okay. Good. That is a clear answer. And then the next one, regarding the probiotic drops. The Protectis Plus, you talked about the launch plan in your key regions going ahead, and maybe the development of the United States versus the current Protectis drops product that we sell?

Unknown 2
22:39 - 22:41

Yes. So we just launched.

Theresa Agnew
22:41 - 23:33

In the UK in May, we actually launched at a baby show with about 3,000 consumers and received very positive feedback on the new product. So the product so far has been launched in the UK, Ireland, and Sweden. Since our announcement on May 7th. And then we will be rolling it out over time in other markets. It all depends on the regulatory situations because this is a new strain. It does take an additional registration in a lot of our markets. So it will take time, such as in the US where you need to have GRAS certification for a new strain. So there are a number of things from a regulatory perspective that will cause the launch to span over many years.

Matthias Radstone
23:36 - 23:49

Okay, good. And in terms of production, is this part of the production investments that you are making now? Or let's say that if you could launch in the US, would that be doable with the production setup that you have?

Unknown 2
23:49 - 23:50

Yes.

Theresa Agnew
23:50 - 24:09

Yes, definitely. We have plenty of capacity. We actually had a new easy dropper line installed, which is actually the main US SKU in an easy dropper format. So that was installed about two years ago. So we have plenty of capacity. And also, we have capacity on our glass bottle line as well.

Matthias Radstone
24:11 - 24:12

Very clear. Thank you very much.

Operator
24:17 - 24:23

There are no more questions at this time. I hand the conference back to the speakers for any closing comments.

Theresa Agnew
24:24 - 24:32

So thank you for your questions. We are happy to present our Q2 results and we will be back again when we have Q3 results. Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…